Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary Sarcoidosis
Status:
Completed
Trial end date:
2019-03-04
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess if ACZ885 will improve lung function in association
with reduction of tissue inflammation in patients with chronic sarcoidosis.